Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients with major depressive disorder (MDD) commonly have many gastrointestinal complaints. Gastrointestinal pain is classified into 2 categories: visceral and somatic pain. The main aim of this study is to compare somatic and visceral sensitivity between healthy people and pateints with MDD. These two sensitivities will be assessed by the 2 following tests: standardized rectal distension and Transdermal transcutaneous electric nerve stimulation. Thereafter, patients with MDD will be randomly allocated to escitalopram or reboxetine. After 6 weeks of treatment, somatic and visceral sensitivity will be reassessed.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | subjects with MDD randomized to Escitalopram |
|
| 2 | Active Comparator | MDD patients receiving reboxetine |
|
| 3 | Other | Healthy volonteers |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| escitalopram | Drug | escitalopram 10 mg/d for 6 weeks |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| rectal distension Transcutaneous Electrical Neuro-Stimulation | 1-7 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Casas Miguel, Prof. | Hospital Universitari Vall d'Hebron Research Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitari vall d'Hebron | Recruiting | Barcelona | Catalonia | 08036 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
| Reboxetine | Drug | Reboxetine 8 mg/d for 6 weeks |
|
| No intervention | Other | This group of healthy volonteers will receive no drug and will be a healthy comparator. |
|
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D010146 | Pain |
| D015746 | Abdominal Pain |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012817 | Signs and Symptoms, Digestive |
Not provided
Not provided
| ID | Term |
|---|---|
| D000089983 | Escitalopram |
| D000077593 | Reboxetine |
| ID | Term |
|---|---|
| D011437 | Propylamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D009570 | Nitriles |
| D001572 | Benzofurans |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D009025 | Morpholines |
| D010078 | Oxazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
Not provided
Not provided